Table 3.
Correlation of various histopathological features with expression of B9L in ductal carcinoma in situ
| Feature | n | B9L | P‐value † | ||
|---|---|---|---|---|---|
| 0 | 1+ | 2+ | |||
| No. cases | 14 | 37 | 51 | ||
| Nuclear grade | |||||
| Low | 24 | 4 | 10 | 10 | 0.010 |
| Intermediate | 42 | 8 | 16 | 18 | |
| High | 36 | 0 | 11 | 25 | |
| Comedo | |||||
| Absence | 59 | 8 | 28 | 23 | 0.035 |
| Presence | 43 | 6 | 9 | 28 | |
| Predominant architecture | |||||
| Cribriform | 31 | 2 | 17 | 12 | 0.418 |
| Solid | 13 | 2 | 6 | 5 | |
| Micropapillary | 24 | 3 | 7 | 14 | |
| Others | 11 | 4 | 2 | 5 | |
| Pure comedo | 23 | 3 | 5 | 15 | |
| β‐catenin | |||||
| 0 | 18 | 6 | 5 | 7 | 0.058 |
| 1 | 55 | 4 | 25 | 26 | |
| 2 | 29 | 4 | 7 | 18 | |
| ErbB2/HER‐2 | |||||
| 0 | 32 | 9 | 11 | 12 | 0.027 |
| 1 | 35 | 4 | 14 | 17 | |
| 2 | 35 | 1 | 12 | 22 | |
| ER | |||||
| 0 | 28 | 2 | 7 | 19 | 0.088 |
| 1 | 13 | 3 | 4 | 6 | |
| 2 | 61 | 9 | 26 | 26 | |
| p53 | |||||
| 0 | 37 | 13 | 12 | 12 | <0.001 |
| 1 | 24 | 1 | 12 | 11 | |
| 2 | 41 | 0 | 13 | 28 | |
| c‐myc | |||||
| 0 | 61 | 12 | 25 | 24 | 0.008 |
| 1 | 30 | 2 | 6 | 22 | |
| 2 | 11 | 0 | 6 | 5 | |
ER, estrogen receptor. †Bold type indicates a significant correlation.